

Mj Garcia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8502873/publications.pdf>

Version: 2024-02-01

42
papers

991
citations

430874

18
h-index

454955

30
g-index

43
all docs

43
docs citations

43
times ranked

1193
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients. <i>Pharmaceutics</i> , 2022, 14, 811.	4.5	3
2	Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 153, 105484.	4.0	1
3	Puesta en marcha de un hospital de día del Área del corazón: análisis de actividad, calidad y coste-efectividad en el primer año de funcionamiento. <i>Revista Española De Cardiología</i> , 2019, 72, 130-137.	1.2	7
4	Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome. <i>JACC: Heart Failure</i> , 2018, 6, 928-936.	4.1	86
5	Comparison of 1-Year Outcome in Patients With Severe Aorta Stenosis Treated Conservatively or by Aortic Valve Replacement or by Percutaneous Transcatheter Aortic Valve Implantation (Data from a Tj ETQq1 1 0.784314 rg06 /Overloc	3.2	17
6	Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1517-1527.	2.4	24
7	Predictive ability of different analytical parameters in Mycophenolate Pharmacokinetics and dosing. <i>Clinical Therapeutics</i> , 2015, 37, e45.	2.5	0
8	Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5314-5324.	3.2	42
9	Vancomycin Dosage Optimization in Patients with Malignant Haematological Disease by Pharmacokinetic/Pharmacodynamic Analysis. <i>Clinical Pharmacokinetics</i> , 2009, 48, 273-280.	3.5	27
10	Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2791-2798.	3.2	65
11	Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. <i>Aids</i> , 2008, 22, 2549-2551.	2.2	12
12	Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 483-489.	2.0	43
13	Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukaemia. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1227-1238.	3.5	86
14	Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4934-4941.	3.2	102
15	Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy. <i>Clinical Pharmacokinetics</i> , 2001, 40, 63-71.	3.5	40
16	Population Kinetics of Tobramycin in Neonates. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 202-208.	2.0	12
17	Valproate population pharmacokinetics in children. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 73-80.	1.5	59
18	Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). <i>Journal of Controlled Release</i> , 1999, 57, 161-169.	9.9	18

#	ARTICLE	IF	CITATIONS
19	Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. , 1999, 20, 233-240.		46
20	Population pharmacokinetics of caffeine in premature neonates. European Journal of Clinical Pharmacology, 1997, 52, 211-217.	1.9	52
21	Carbamazepine Population Pharmacokinetics in Children. Therapeutic Drug Monitoring, 1997, 19, 132-139.	2.0	31
22	Bayesian Forecasting in Paediatric Populations. Clinical Pharmacokinetics, 1996, 31, 325-330.	3.5	23
23	Predictive Performance of Two Phenytoin Pharmacokinetic Dosing Programs from Nonsteady State Data. Therapeutic Drug Monitoring, 1994, 16, 380-387.	2.0	12
24	Dosage programming of phenobarbital in neonatal seizures. Journal of Clinical Pharmacy and Therapeutics, 1993, 18, 267-270.	1.5	11
25	Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. Journal of Clinical Pharmacy and Therapeutics, 1993, 18, 191-197.	1.5	42
26	Population pharmacokinetics of imipramine in children. European Journal of Clinical Pharmacology, 1992, 43, 89-92.	1.9	6
27	Influence of length of treatment on the interaction between phenobarbital and phenytoin. Journal of Clinical Pharmacy and Therapeutics, 1992, 17, 49-50.	1.5	7
28	Dosage optimization methods applied to imipramine and desipramine in enuresis treatment. Journal of Clinical Pharmacy and Therapeutics, 1992, 17, 55-59.	1.5	2
29	COMPARISON OF TWO METHODS IN THE ESTIMATION OF THE PHARMACOKINETIC PARAMETERS OF PHENYTOIN. Journal of Clinical Pharmacy and Therapeutics, 1990, 15, 225-231.	1.5	2
30	The influence of clinical and pharmacological factors on enuresis treatment with imipramine.. British Journal of Clinical Pharmacology, 1990, 30, 693-698.	2.4	8
31	Predictive Techniques Applied to Imipramine Therapeutic Drug Monitoring. DICP: the Annals of Pharmacotherapy, 1989, 23, 389-394.	0.2	0
32	TDM OF THEOPHYLLINEâ€™COMPLIANCE EVALUATION. Journal of Clinical Pharmacy and Therapeutics, 1988, 13, 273-280.	1.5	3
33	COMPARISON OF METHODS OF CARBAMAZEPINE DOSAGE, INDIVIDUALIZATION IN EPILEPTIC PATIENTS. Journal of Clinical Pharmacy and Therapeutics, 1988, 13, 375-380.	1.5	10
34	Theophylline Monitoring and Noncompliance in Chronic Bronchial Asthma. Drug Intelligence & Clinical Pharmacy, 1988, 22, 633-634.	0.4	0
35	Effect of Sodium Valproate on Phenobarbital Serum Levels in Children and Adults. Therapeutic Drug Monitoring, 1986, 8, 416-420.	2.0	8
36	Pharmacokinetics of cefoxitin administered by i.v. infusion to patients with a pleural effusion. European Journal of Clinical Pharmacology, 1984, 26, 389-392.	1.9	3

#	ARTICLE	IF	CITATIONS
37	Monitoring of Serum Levels of Imipramine and Desipramine and Individualization of Dose in Enuretic Children. <i>Therapeutic Drug Monitoring</i> , 1984, 6, 438-443.	2.0	26
38	Pharmacokinetics of cefoxitin during haemofiltration. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 395-398.	1.9	11
39	Pharmacokinetics of cefoxitin administered intramuscularly to rabbits with experimentally-induced renal impairment. <i>Biopharmaceutics and Drug Disposition</i> , 1981, 2, 205-213.	1.9	0
40	Disposition of Cefoxitin in patients with ascites. <i>European Journal of Clinical Pharmacology</i> , 1981, 20, 371-374.	1.9	5
41	Influence of experimental renal impairment in the pharmacokinetics of cefoxitin after intravenous administration to rabbits. <i>International Journal of Pharmaceutics</i> , 1980, 5, 117-125.	5.2	3
42	Pharmacokinetics of cefoxitin in patients with normal or impaired renal function. <i>European Journal of Clinical Pharmacology</i> , 1979, 16, 119-124.	1.9	24